Spectrum Pharmaceuticals, Inc.- Product Portfolio

Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Products in Late Stage Development

Spectrum's late-stage drug candidates include belinostat, an HDAC inhibitor in late-stage clinical development for peripheral T-cell lymphoma, and other solid tumors (including Carcinoma of Unknown Primary origin, etc.), and apaziquone, a synthetic bio-reductive agent being investigated in the treatment of non muscle-invasive bladder cancer. Both drugs are being developed under Special Protocol Assessment (SPA) by the FDA.

This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the beliefs of the Company's management as well as assumptions made by and information currently available to the Company's management. Readers should not put undue reliance on these forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Spectrum Pharmaceuticals, Inc.'s actual results may differ materially from the results projected in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed in the Company's most recent Form 10-K and 10-Qs. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this filing except as required by law.

Site Map | Privacy Policy | Terms of Use | Linking Policy
Contact Us | Webmail

Products in Late Stage Development

Our Company

Product Portfolio

Investor Relations

Patient Information

Medical Professionals

Contact Us